NEJM’s colorful explanation of how radium-223 targets bone metastases

Last month, a study published in The New England Journal of Medicine (NEJM) demonstrated how radium-223 could reduce the risk of death in patients with castration-resistant prostate cancer by targeting bone metastases, a common complication.

To help bring the research to life, NEJM created the following Quick Take animation: